Mineralys Therapeutics, Inc. (MLYS) Misses Q3 EPS by 42c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q3 EPS of ($1.13), $0.42 worse than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Flowers Foods (FLO) files mixed shelf
• Gamma Resources raises private placement ceiling to $1.75M